Exposing the LASIK Scam

For the fourth quarter, it posted a net loss of $12.3 million, or 20 cents per share, compared with a year-earlier loss of $7.6 million, or 13 cents per share.

The company said its 2008 outlook assumes a 10 percent decline in its U.S. excimer vision correction procedures, compared with its prior expectation of 6 percent growth. It also assumes a more modest rate of growth for its U.S. femtosecond correction procedure and for sales of refractive intraocular lenses, artificial implanted lenses, than previously expected.